GEP20135999B - Usage of composition comprising formoterol and beclometasone dipropionate for prevention and/or treatment of asthma exacerbation - Google Patents

Usage of composition comprising formoterol and beclometasone dipropionate for prevention and/or treatment of asthma exacerbation

Info

Publication number
GEP20135999B
GEP20135999B GEAP2008011515A GEP20135999B GE P20135999 B GEP20135999 B GE P20135999B GE AP2008011515 A GEAP2008011515 A GE AP2008011515A GE P20135999 B GEP20135999 B GE P20135999B
Authority
GE
Georgia
Prior art keywords
formoterol
usage
prevention
treatment
composition
Prior art date
Application number
Inventor
Paolo Chiesi
Ivano Rondelli
Daniela Acerbi
Gianluigi Poli
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to EP07007930A priority Critical patent/EP1982709A1/en
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of GEP20135999B publication Critical patent/GEP20135999B/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38458097&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GEP20135999(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

The present invention relates to: a) formoterol, pharmaceutically acceptable salt or solvate or solva¬te of salt thereof; and b) application of compo¬sition comprising beclometasone dipropionate for inhala¬tion medicament preparation to remove acute asthma episodes by application of same composition during maintenance therapy of asthma.
GEAP2008011515 2007-04-19 2008-04-16 Usage of composition comprising formoterol and beclometasone dipropionate for prevention and/or treatment of asthma exacerbation GEP20135999B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07007930A EP1982709A1 (en) 2007-04-19 2007-04-19 Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma

Publications (1)

Publication Number Publication Date
GEP20135999B true GEP20135999B (en) 2014-01-10

Family

ID=38458097

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP2008011515 GEP20135999B (en) 2007-04-19 2008-04-16 Usage of composition comprising formoterol and beclometasone dipropionate for prevention and/or treatment of asthma exacerbation

Country Status (29)

Country Link
US (1) US20080261932A1 (en)
EP (3) EP1982709A1 (en)
JP (2) JP5492072B2 (en)
KR (3) KR20100014408A (en)
CN (1) CN101657191B (en)
AU (1) AU2008241045B2 (en)
BR (1) BRPI0809800A2 (en)
CA (1) CA2684539A1 (en)
CO (1) CO6220945A2 (en)
CY (1) CY1117568T1 (en)
DK (1) DK2146704T3 (en)
EA (1) EA018589B1 (en)
ES (2) ES2740103T3 (en)
GE (1) GEP20135999B (en)
HK (1) HK1137357A1 (en)
HR (1) HRP20160588T1 (en)
HU (1) HUE029263T2 (en)
IL (1) IL201632A (en)
MA (1) MA31315B1 (en)
ME (1) ME00945B (en)
MX (1) MX2009010851A (en)
NZ (1) NZ580526A (en)
PL (2) PL3034073T3 (en)
RS (1) RS54874B1 (en)
SI (1) SI2146704T1 (en)
TN (1) TN2009000390A1 (en)
TR (1) TR201909857T4 (en)
UA (1) UA100237C2 (en)
WO (1) WO2008128685A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1982709A1 (en) 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma
CN102548537B (en) * 2009-10-02 2014-06-25 奇斯药制品公司 Pharmaceutical aerosol formulations of formoterol and beclometasone dipropionate
CN102247597B (en) * 2010-05-19 2015-01-07 天津金耀集团有限公司 Novel inhalant containing glucocorticoid and bronchodilator
PL2806855T3 (en) * 2012-01-25 2018-12-31 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
US11052202B2 (en) * 2012-11-07 2021-07-06 Chiesi Farmaceutici S.P.A. Drug delivery device for the treatment of patients with respiratory diseases
GEP20217240B (en) * 2016-09-19 2021-03-25 Mexichem Fluor Sa De Cv Pharmaceutical composition
CN107233311B (en) * 2017-06-27 2020-12-04 长风药业股份有限公司 Atomizing agent with arformoterol and glycopyrronium bromide as active ingredients and preparation method thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
JP3342484B2 (en) 1991-12-18 2002-11-11 アストラ・アクチエボラーグ New formulation
SE9802073D0 (en) 1998-06-11 1998-06-11 Astra Ab New use
AU2000250701B2 (en) 2000-05-22 2004-07-01 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
FI20002177A0 (en) * 2000-10-02 2000-10-02 Orion Yhtymae Oyj New combination for asthma therapy
FI20002216A0 (en) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Combination particles for asthma therapy
FI20002215A0 (en) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Combination Particles
GEP20063986B (en) 2002-03-01 2006-12-11 Chiesi Farma Spa Formoterol superfine formulation
EP1982709A1 (en) 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma

Also Published As

Publication number Publication date
JP5492072B2 (en) 2014-05-14
NZ580526A (en) 2012-07-27
JP2010524873A (en) 2010-07-22
MX2009010851A (en) 2009-11-05
EA200901201A1 (en) 2010-04-30
PL3034073T3 (en) 2019-11-29
EP3034073B1 (en) 2019-06-12
BRPI0809800A2 (en) 2014-10-07
DK2146704T3 (en) 2016-05-23
TR201909857T4 (en) 2019-07-22
US20080261932A1 (en) 2008-10-23
AU2008241045A1 (en) 2008-10-30
HUE029263T2 (en) 2017-02-28
CA2684539A1 (en) 2008-10-30
TN2009000390A1 (en) 2010-12-31
KR20100014408A (en) 2010-02-10
ES2740103T3 (en) 2020-02-05
MA31315B1 (en) 2010-04-01
EP2146704B1 (en) 2016-03-23
SI2146704T1 (en) 2016-05-31
EP1982709A1 (en) 2008-10-22
CN101657191B (en) 2014-06-11
EP3034073A1 (en) 2016-06-22
ES2568497T3 (en) 2016-04-29
EP2146704A1 (en) 2010-01-27
PL2146704T3 (en) 2016-09-30
CO6220945A2 (en) 2010-11-19
IL201632A (en) 2016-09-29
KR20150082699A (en) 2015-07-15
KR20150038618A (en) 2015-04-08
HRP20160588T1 (en) 2016-07-01
RS54874B1 (en) 2016-10-31
ME00945B (en) 2012-06-20
HK1137357A1 (en) 2010-07-30
EA018589B1 (en) 2013-09-30
AU2008241045B2 (en) 2013-06-20
KR101668203B1 (en) 2016-10-20
UA100237C2 (en) 2012-12-10
IL201632D0 (en) 2010-05-31
CY1117568T1 (en) 2017-04-26
KR101621676B1 (en) 2016-05-16
JP2014005312A (en) 2014-01-16
WO2008128685A1 (en) 2008-10-30
CN101657191A (en) 2010-02-24

Similar Documents

Publication Publication Date Title
GEP20135999B (en) Usage of composition comprising formoterol and beclometasone dipropionate for prevention and/or treatment of asthma exacerbation
IL233677A (en) Substituted benzisoxazole aminopyrazolo-pyrimidine compounds, pharmaceutical compositions comprising them and use of the compounds for the manufacture of medicaments
EP2749280A3 (en) Combination of glycopyrronium and formoterol
GB201104241D0 (en) Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administrating same
WO2010127099A3 (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
IL250439D0 (en) Use of fingolimod, or a phosphate derivative thereof or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of multiple sclerosis
MX2011008171A (en) Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof.
WO2007027527A3 (en) Isoindole-imide compounds and compositions comprising and methods of using the same
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
UA93709C2 (en) 12-imidazolyl-1-dodecanol and use thereof in the preparation of pharmaceutical compositions
MX2012000488A (en) Combination therapy for the treatment of diabetes.
EP2004576A4 (en) New method for the manufacture of therapeutic compounds and compositions, compounds and compositions produced therewhith, and their use
WO2010151565A3 (en) Combination therapies for the treatment of obesity
EP2217238A4 (en) Methods and compositions for the treatment of proteinuric diseases
ZA201101278B (en) Compounds,compositions and methods for the treatment of b-amyloid diseases and synucleinopathies
TWI369988B (en) New pharmaceutically active compounds for the treatment of respiratory diseases
IL240394A (en) Use of alemtuzumab for the preparation of a medicament for use as a second line therapy for the treatment of multiple sclerosis (ms)
IL207420A (en) Pharmaceutical composition comprising rifabutin, clarithromycin and clofazimine and a method of formulating the composition
WO2010151503A3 (en) Combination therapies for the treatment of obesity
WO2008104852A3 (en) Pharmaceutical compositions comprising adsorbate of fenofibrate
EP2168586A4 (en) Active ingredient of a medicinal agent, a medicinal agent, a pharmaceutical composition and method for treating dementia syndrome patients
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
WO2005120518A3 (en) Use of atp analogues for treatment of cardiovascular diseases
WO2008039894A3 (en) Atorvastatin pharmaceutical compositions
WO2008004100A3 (en) Therapeutic compounds